ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

LYEL vs JNJ // GROSS PROFIT MARGIN

Lyell Immunopharma Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: LYEL 0 — JNJ 7
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LYEL VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC LYEL JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — 67.90% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 25.50% -60.50 JNJ /roic <GO>
EV/EBITDA & P/E Valuation — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield — 2.97% — TIE /fcf-yield <GO>
Operating Margin -60.00% 34.70% -94.70 JNJ /operating-margins <GO>
Net Profit Margin -60.00% 28.50% -88.50 JNJ /net-margins <GO>
Revenue Growth (YoY) -41.00% 6.00% -47.00 JNJ /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.59 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 8/9 -5.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 61.4 62.1 -0.70 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 23.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $277.0M $662.49B -$662.21B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR LYEL REV JNJ REV LYEL GROSS % JNJ GROSS % LYEL FCF JNJ FCF
FY 2025 $36.0K $94.19B — 67.9% -$150.8M $19.70B
FY 2024 $61.0K $88.82B — 69.1% -$162.9M $19.84B
FY 2023 $130.0K $85.16B — — -$163.7M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LYEL // BETA —
JNJ // BETA 1.08